This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Synthetic pentasaccharides

Authoring team

  • pentasaccharides are synthetic drugs that accelerate the interaction between factor Xa and antithrombin
    • induce a conformational change in antithrombin
      • unlike unfractionated and low-molecular-weight heparins, pentasaccharides do not affect the interaction of antithrombin with thrombin and thus selectively inhibit factor Xa activity
      • fondaparinux is a pentasaccharide with a half-life of approximately 17 hours
      • idraparinux is a long-acting pentassacharide, with a half-life of about 80 hours

A table comparing the properties of pentasaccarides to low molecular weight heparin is presented below:

Property

Pentasaccarides

Low molecular weight heparin

monitoring requirement

no*

no*

bioavailability

complete

very high

plasma protein binding

none

low

renal clearance

yes

yes

dose-dependent clearance

no

no

risk of heparin-induced thrombocytopaenia

no**

low

safety in pregnancy

not known

yes

route of administration

subcutaenous

subcutaneous

neutralised by protamine sulphate

no

partial

half-life (hours)

3-6 hours

fondaparinux 17 hours

* monitoring is required in patients with a creatinin clearance of less than 30 ml/min by anti-Xa concentrations.

** low-molecular-weight heparins are less likely to induce thrombocytopenia than unfractionated heparin, because these interact less with platelets and platelet factor 4 (an essential feature of heparin-induced thrombocytopenia). Pentasaccharides do not interact with platelet factor 4 and platelets and thus are very unlikely to induce thrombocytopaenia (1).

Trial evidence suggest that fondaparinux is as good as, and possibly better than, low molecular-weight heparin for the prophylaxis of post-operative deep venous thrombosis in patients undergoing hip replacement (2).

Reference:

  • (1) Savi P et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005;105 (1): 139-144.
  • (2) BMJ. 2006 Jan 28;332(7535):215-9.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.